Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021


◆タイトル:Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥381,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥545,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。





About Hospital Acquired Pneumonia (HAP) Drugs
HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.

Technavio’s analysts forecast the global hospital acquired pneumonia drugs market to grow at a CAGR of 2.22% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global hospital acquired pneumonia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Hospital Acquired Pneumonia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer

[Other prominent vendors]
• Arsanis
• AstraZeneca
• Combioxin
• Mylan
• Shinogi
• Sun Pharmaceutical Industries
• Teva Pharmaceutical
• The Medicines Company
• Theravance Biopharma

[Market driver]
• Unmet demand due to lack of available treatment for MDR microorganisms
• For a full, detailed list, view our report

[Market challenge]
• Growing cases of MDR microorganisms
• For a full, detailed list, view our report

[Market trend]
• Combination therapy for the treatment of HAP
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Pneumonia
• Types of pneumonia

PART 06: Market landscape
• Market overview
• Market size and forecast

PART 07: Pipeline analysis

PART 08: Market segmentation by drug class
• Antibacterial drug
• Antiviral drugs
• Others

PART 09: Geographical segmentation
• HAP drugs market in Americas
• HAP drugs market in EMEA
• HAP drugs market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Combination therapy for the treatment of HAP
• Growing preference for accurate diagnosis of disease
• Rising R&D for effective treatment against superbugs/MDR microorganisms

PART 13: Vendor landscape
• Competitive landscape

PART 14: Key vendor analysis
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Classification of pneumonia
Exhibit 02: Types of HAP
Exhibit 03: Symptoms and tests of HAP
Exhibit 04: Global HAP drugs market snapshot
Exhibit 05: Global HAP drugs market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis of HAP drugs market
Exhibit 07: Five forces analysis
Exhibit 08: Key pipeline molecules by vendors
Exhibit 09: Pipeline landscape
Exhibit 10: Segmentation of global HAP drugs market by drug class
Exhibit 11: Global HAP drugs market share by drug class 2016 and 2021
Exhibit 12: Uses and side effects of antibacterial drug
Exhibit 13: Global HAP antibacterial drugs market 2016-2021 ($ millions)
Exhibit 14: Causative microorganisms and empiric treatment
Exhibit 15: Brand mixtures for piperacillin-tazobactam
Exhibit 16: Global HAP antiviral drugs market 2016-2021 ($ millions)
Exhibit 17: Global HAP others drugs market 2016-2021 ($ millions)
Exhibit 18: Segmentation of global HAP drugs market based on geography 2016 and 2021
Exhibit 19: Global HAP drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 20: Market scenario in Americas
Exhibit 21: HAP drugs market in Americas 2016-2021 ($ millions)
Exhibit 22: Market scenario in EMEA
Exhibit 23: HAP drugs market in the EMEA 2016-2021 ($ millions)
Exhibit 24: Market scenario in APAC
Exhibit 25: HAP drugs market in the APAC 2016-2021 ($ millions)
Exhibit 26: Average percentage distribution of transplants by organ in US 1988-2016
Exhibit 27: Competitive structure analysis of global HAP drugs market 2016
Exhibit 28: GlaxoSmithKline: Key highlights
Exhibit 29: GlaxoSmithKline: Strength assessment
Exhibit 30: GlaxoSmithKline: Strategy assessment
Exhibit 31: GlaxoSmithKline: Opportunity assessment
Exhibit 32: Merck: Key highlights
Exhibit 33: Merck: Strength assessment
Exhibit 34: Merck: Strategy assessment
Exhibit 35: Merck: Opportunity assessment
Exhibit 36: Novartis: Key highlights
Exhibit 37: Novartis: Strength assessment
Exhibit 38: Novartis: Strategy assessment
Exhibit 39: Novartis: Opportunity assessment
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment


GlaxoSmithKline, Merck, Novartis, Pfizer, Arsanis, AstraZeneca, Combioxin, Mylan, Shinogi, Sun Pharmaceutical Industries, Teva Pharmaceutical, The Medicines Company, and Theravance Biopharma.